Form 4: Foghorn Therapeutics CEO Transfers Shares to Grantor Retained Annuity Trust
SEC Form 4 Filing
CEO Adrian Gottschalk transferred 300,000 shares of Foghorn Therapeutics stock from his living trust to a grantor retained annuity trust on April 25, 2025.
Summary
- On April 25, 2025, Adrian Gottschalk, CEO of Foghorn Therapeutics, transferred 300,000 shares of the company's common stock from the Adrian H. Gottschalk Living Trust to the Adrian H. Gottschalk 2025 Grantor Retained Annuity Trust.
- Gottschalk serves as the trustee for both trusts and is the sole current beneficiary of the 2025 GRAT.
- Following the transaction, Gottschalk beneficially owns a total of 511,704 shares indirectly.
- This includes 47,497 shares held by the Adrian H. Gottschalk 2023 Grantor Retained Annuity Trust, 300,000 shares held by the Gottschalk 2025 GRAT, and 164,207 shares held by the Gottschalk Living Trust.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing a stock transfer. It doesn't convey any positive or negative sentiment about the company's performance or prospects.
Industry Context
This is a routine disclosure of insider transactions and doesn't necessarily reflect a change in the company's outlook or performance.
Key Dates
| Date | Description |
|---|---|
| 2009-09-08 | Date of the Adrian H. Gottschalk Living Trust |
| 2023-05-26 | Date of the Adrian H. Gottschalk 2023 Grantor Retained Annuity Trust |
| 2025-04-25 | Date of stock transfer and creation of the Adrian H. Gottschalk 2025 Grantor Retained Annuity Trust |
| 2025-04-28 | Date of Form 4 filing |
Keywords
Foghorn Therapeutics, Adrian Gottschalk, stock transfer, Form 4, beneficial ownership, grantor retained annuity trust, living trust, FHTX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.